Journal of Clinical Pediatrics ›› 2019, Vol. 37 ›› Issue (6): 409-.doi: 10.3969/j.issn.1000-3606.2019.06.003
Previous Articles Next Articles
WANG Xiufang, LI Weixia, ZHANG Yanli, SONG Zhe
Online:
Published:
Abstract: Objective To analyze the clinical features and laboratory results of Mycoplasma pneumoniae necrotizing pneumonia (MPNP) in children, and to search for early diagnostic indicators of MPNP. Method The clinical data of MPNP in 40 children and refractory Mycoplasma pneumoniae pneumonia (RMPP) in 60 children were retrospectively analyzed. The differences between the two groups were compared, and ROC curves were drawn to find the indicators to predict the occurrence of MPNP. Results The hospitalization time, fever duration, the proportion of liver injury and pleural effusion, peripheral white blood cell (WBC) count, neutrophil ratio, C-reactive protein, D-dimer and lactate dehydrogenase in MPNP group were significantly higher than those in RMPP group, and there were significant differences (all P<0.05). Multivariate logistic regression analysis showed that WBC (OR=1.35, 95%CI: 1.09~1.68) and fever time (OR=1.22, 95%CI: 1.03~1.44) were risk factors for MPNP (all P<0.05). The ROC curves of WBC and fever duration for predicting MPNP were drawn. It was found that WBC>12.6×109/L and fever duration >13.5 days were of high value in predicting MPNP (AUC=0.80, 0.83, all P<0.001). Conclusion When fever duration was >13.5 days and WBC was >12.6×109/L in children with lobar pneumonia induced by Mycoplasma pneumoniae, the clinician should be alerted to occurrence of MPNP.
Key words: Mycoplasma pneumoniae; necrotizing pneumonia; predictive indicator; child
WANG Xiufang, LI Weixia, ZHANG Yanli, et al. Study on predictive indicators of Mycoplasma Pneumoniae pneumoniae necrotizing pneumonia in children[J].Journal of Clinical Pediatrics, 2019, 37(6): 409-.
0 / / Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: https://jcp.xinhuamed.com.cn/EN/10.3969/j.issn.1000-3606.2019.06.003
https://jcp.xinhuamed.com.cn/EN/Y2019/V37/I6/409
Cited